Repligen Co. (NASDAQ:RGEN) Shares Bought by Two Sigma Advisers LP

Two Sigma Advisers LP raised its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 6.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 134,800 shares of the biotechnology company's stock after acquiring an additional 8,500 shares during the quarter. Two Sigma Advisers LP owned approximately 0.24% of Repligen worth $19,403,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in RGEN. Signaturefd LLC raised its holdings in shares of Repligen by 172.2% during the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 124 shares during the last quarter. Sava Infond d.o.o. acquired a new position in shares of Repligen during the fourth quarter valued at approximately $29,000. Raiffeisen Bank International AG acquired a new position in shares of Repligen during the fourth quarter valued at approximately $29,000. Itau Unibanco Holding S.A. acquired a new stake in shares of Repligen in the fourth quarter valued at approximately $40,000. Finally, UMB Bank n.a. increased its holdings in shares of Repligen by 49.1% in the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock valued at $48,000 after purchasing an additional 110 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Insider Transactions at Repligen

In related news, Director Margaret Pax bought 250 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The stock was purchased at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the acquisition, the director now owns 1,043 shares in the company, valued at approximately $157,169.67. This trade represents a 31.53% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 1.20% of the company's stock.

Repligen Trading Up 4.5%

Shares of RGEN traded up $5.31 during midday trading on Tuesday, hitting $123.46. 93,676 shares of the stock were exchanged, compared to its average volume of 744,484. Repligen Co. has a 52-week low of $102.96 and a 52-week high of $182.52. The stock has a fifty day simple moving average of $129.75 and a 200 day simple moving average of $144.33. The firm has a market cap of $6.94 billion, a P/E ratio of -242.08, a P/E/G ratio of 4.54 and a beta of 1.21. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, topping the consensus estimate of $0.35 by $0.04. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The business had revenue of $169.17 million during the quarter, compared to analyst estimates of $163.65 million. During the same period last year, the business posted $0.28 earnings per share. The company's quarterly revenue was up 10.4% on a year-over-year basis. On average, research analysts anticipate that Repligen Co. will post 1.72 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. TD Cowen assumed coverage on Repligen in a report on Monday, February 10th. They issued a "buy" rating and a $200.00 price target for the company. Canaccord Genuity Group cut their price target on Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a report on Wednesday, April 16th. Wall Street Zen raised Repligen from a "sell" rating to a "hold" rating in a report on Thursday, May 8th. HC Wainwright reaffirmed a "buy" rating and issued a $180.00 price target on shares of Repligen in a report on Monday, May 5th. Finally, Wolfe Research raised Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price target for the company in a report on Tuesday, April 29th. Six analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $173.25.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.